Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes
Diabetologia · 2024-09 · 67 (9) · 1731-1759
DOI: 10.1007/s00125-024-06205-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetologia, online erschienen am 24.06.2024. Verfasst von Moshe Phillip und 59 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel. Hauptthemen laut MEDLINE: Autoantibodies, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Given the proven benefits of screening to reduce diabetic ketoacidosis (DKA) likelihood at the time of stage 3 type 1 diabetes diagnosis, and emerging availability of therapy to delay disease progression, type 1 diabetes screening programmes are being increasingly emphasised. Once broadly implemented, screening initiatives will identify significant numbers of islet autoantibody-positive (IAb + ) children and adults who are at risk of (confirmed single IAb + ) or living with (multiple IAb + ) early-stage (stage 1 and stage 2) type 1 diabetes. These individuals will need monitoring for disease progression; much of this care will happen in non-specialised settings. To inform this monitoring, JDRF in conjunction with international experts and societies developed consensus guidance. Broad advice from this guidance includes the following: (1) partnerships should be fostered between endocrinologists and primary-care providers to care for people who are IAb + ; (2) when people who are IAb + are initially identified there is a need for confirmation using a second sample; (3) single IAb + individuals are at lower risk of progression than multiple IAb + individuals; (4) individuals with early-stage type 1 diabetes should have periodic medical monitoring, including regular assessments of glucose levels, regular education about symptoms of diabetes and DKA, and psychosocial support; (5) interested people with stage 2 type 1 diabetes should be offered trial participation or approved therapies; and (6) all health professionals involved in monitoring and care of individuals with type 1 diabetes have a responsibility to provide education. The guidance also emphasises significant unmet needs for further research on early-stage type 1 diabetes to increase the rigour of future recommendations and inform clinical care. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
- Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.
- Forschergruppe Diabetes, Technical University Munich, Klinikum Rechts Der Isar, Munich, Germany.
- Division of Endocrinology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
- Stanford Diabetes Research Center, Stanford University School of Medicine, Stanford, CA, USA.
Zitieren
APA
Phillip, M., Achenbach, P., Addala, A., Albanese-O'Neill, A., Battelino, T., Bell, K. J., Besser, R. E. J., Bonifacio, E., Colhoun, H. M., Couper, J. J., Craig, M. E., Danne, T., de Beaufort, C., Dovc, K., Driscoll, K. A., Dutta, S., Ebekozien, O., Larsson, H. E., Feiten, D. J., …, & Tonyushkina, K. N. (2024). Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetologia, 67(9), 1731-1759. https://doi.org/10.1007/s00125-024-06205-5
Vancouver
Phillip M, Achenbach P, Addala A, Albanese-O'Neill A, Battelino T, Bell KJ, et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetologia. 2024;67(9):1731-1759. doi:10.1007/s00125-024-06205-5
BibTeX
@article{Phillip2024,
author = {Phillip, Moshe and Achenbach, Peter and Addala, Ananta and Albanese-O'Neill, Anastasia and Battelino, Tadej and Bell, Kirstine J and Besser, Rachel E J and Bonifacio, Ezio and Colhoun, Helen M and Couper, Jennifer J and Craig, Maria E and Danne, Thomas and de Beaufort, Carine and Dovc, Klemen and Driscoll, Kimberly A and Dutta, Sanjoy and Ebekozien, Osagie and Larsson, Helena Elding and Feiten, Daniel J and Frohnert, Brigitte I and Gabbay, Robert A and Gallagher, Mary P and Greenbaum, Carla J and Griffin, Kurt J and Hagopian, William and Haller, Michael J and Hendrieckx, Christel and Hendriks, Emile and Holt, Richard I G and Hughes, Lucille and Ismail, Heba M and Jacobsen, Laura M and Johnson, Suzanne B and Kolb, Leslie E and Kordonouri, Olga and Lange, Karin and Lash, Robert W and Lernmark, Åke and Libman, Ingrid and Lundgren, Markus and Maahs, David M and Marcovecchio, M Loredana and Mathieu, Chantal and Miller, Kellee M and O'Donnell, Holly K and Oron, Tal and Patil, Shivajirao P and Pop-Busui, Rodica and Rewers, Marian J and Rich, Stephen S and Schatz, Desmond A and Schulman-Rosenbaum, Rifka and Simmons, Kimber M and Sims, Emily K and Skyler, Jay S and Smith, Laura B and Speake, Cate and Steck, Andrea K and Thomas, Nicholas P B and Tonyushkina, Ksenia N},
title = {Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes},
journal = {Diabetologia},
year = {2024},
volume = {67},
number = {9},
pages = {1731--1759},
doi = {10.1007/s00125-024-06205-5}
}
EUVIMED